Back to results
US 12,747,477 B2Granted
Tumor marker stamp-EP3 based on methylation modification
AssigneeShanghai Epiprobe Biotechnology Co., Ltd.
InventorsZhenyan Li, Shihua Dong
Life of this patent
Estimating the term…
Abstract
The present invention provides a methylation tumor marker STAMP-EP3 and use thereof, and belongs to the field of disease diagnosis markers. The present invention provides use of the methylation tumor marker STAMP-EP3 in the preparation of a tumor diagnosis reagent.
Claims14
A method for detecting one or more tumors comprising:
- treating DNA extracted from one or more samples comprising tumor cells with a reagent that modifies DNA in a methylation-specific manner;
- detecting a modification of a CpG site of a polynucleotide using a tumor detection agent or kit, wherein the polynucleotide is:
- a fragment obtained by amplifying human genomic DNA treated with bisulfite using primers SEQ ID NO:
- 7 and SEQ ID NO:
- 8;
- wherein detecting the modification of a CpG site is performed using methods including pyrosequencing, bisulfite conversion sequencing, methylation chip, qPCR, digital PCR, second generation sequencing, third generation sequencing, whole genome methylation sequencing, DNA enrichment detection, simplified bisulfite sequencing technology, HPLC, MassArray, methylation specific PCR, or any combination thereof;
- and
- wherein the one or more tumors are selected from breast cancer, a leukemia, a colorectal cancer, a liver cancer, a lung cancer, a pancreatic cancer, and esophageal cancer.
5 more elements
A method of preparing a pan-cancer detection agent, comprising:
- providing a polynucleotide and designing a detection agent for specifically detecting the modification of the CpG(s) of the target sequence which is a fragment obtained by amplifying human genomic DNA treated with bisulfite using primers SEQ ID NO:
- 7 and SEQ ID NO:
- 8.
A method of detecting the methylation profile of a sample in vitro, comprising:
- (i) providing the sample and extracting nucleic acid;
- (ii) detecting modification on CPG site(s) of a target sequence in the nucleic acid of (i), wherein the target sequence is a polynucleotide consisting of a fragment obtained by amplifying human genomic DNA treated with bisulfite using primers SEQ ID NO:
- 7 and SEQ ID NO:
- 8.
1 more element
Dependencies are inferred from the claim text.